Extending the benefits of adjuvant therapy in early HR+ breast cancer

Breast Cancer Research and Treatment

Volumn 112, Issue SUPPL. 1, 2008, Pages 45-52

  Goss, Paul E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Adjuvant; Aromatase inhibitor; Early breast cancer; Letrozole

Indexed keywords

ANASTROZOLE; CALCIUM; EXEMESTANE; HORMONE RECEPTOR; LETROZOLE; PLACEBO; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; ARTHRITIS; ARTICLE; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG TOLERABILITY; EARLY CANCER; FRACTURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; MUSCULOSKELETAL PAIN; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; NITRILES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TRIAZOLES;

EID: 58249095126     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0129-8     Document Type: Article

References (40)

1. M Clemons PE Goss 2001 Mechanisms of disease: estrogen and the risk of breast cancer N Engl J Med 344 276 285 10.1056/NEJM200101253440407
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0
3. B Fisher JH Jeong J Bryant 2004 Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Lancet 364 858 868 10.1016/S0140-6736(04)16981-X
4. LE Rutqvist H Johansson Stockholm Breast Cancer Study Group 2007 Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer Acta Oncol 46 133 145
5. T Saphner DC Tormey R Gray 1996 Annual hazard rates of recurrence for breast cancer after primary therapy J Clin Oncol 14 2738 2746
6. GN Hortobagyi SW Kau AU Buzdar 2004 What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? J Clin Oncol 22 14s 10.1200/JCO.2004.02.927 Abstract 585
7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1998 Tamoxifen for early breast cancer: an overview of the randomized trials Lancet 351 1451 1467 10.1016/S0140-6736(97)11423-4
8. B Fisher J Dignam J Bryant N Wolmark 2001 Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial J Natl Cancer Inst 93 684 690 10.1093/jnci/93.9.684
9. AE Wakeling B Valcaccia E Newboult LR Green 1984 Non-steroidal anti-oestrogens-receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells J Steroid Biochem 20 111 120 10.1016/0022-4731(84)90197-3
10. VC Jordan 1994 Molecular mechanisms of antiestrogen action in breast cancer Breast Cancer Res Treat 31 41 52 10.1007/BF00689675
11. VC Jordan 2006 The science of selective estrogen receptor modulators: concept to clinical practice Clin Cancer Res 12 5010 5013 10.1158/1078-0432.CCR- 06-1136
12. HU Bryant WH Dere 1998 Selective estrogen modulators: an alternative to hormone replacement therapy Proc Soc Exp Biol Med 217 45 52
13. MM Gottardis VC Jordan 1988 Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res 48 5183 5187
14. CK Osborne 1993 Mechanisms for tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism J Steroid Biochem Mol Biol 47 83 89 10.1016/0960-0760(93)90060-A
15. CK Osborne E Coronado DC Allred 1991 Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen J Natl Cancer Inst 83 1477 1482 10.1093/jnci/83.20.1477
16. Peto R, Davies C, on behalf of the ATLAS Collaboration (2007) ATLAS (adjuvant tamoxifen, longer against shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11 500 women preliminary results. Breast Cancer Res Treat 106(Suppl 1). Abstract 48
17. Fletcher-Louis M, Ireland S (2000) Onkos study 48: breast cancer. Decision Resources, Waltham
18. RC Coombes E Hall LJ Gibson 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 10.1056/NEJMoa040331
19. A Howell J Cuzick M Baum 2005 Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62 10.1016/S0140-6736(05)74803-0
20. Thürlimann B, on behalf of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757. doi: 10.1056/NEJMoa052258
21. PE Goss JN Ingle S Martino 2003 A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer N Engl J Med 349 1793 1802 10.1056/NEJMoa032312
22. PE Goss JN Ingle S Martino 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262 1271
23. JN Ingle D Tu JL Pater 2006 Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial Breast Cancer Res Treat 99 295 300 10.1007/s10549-006-9207-y
24. PE Goss JN Ingle MJ Palmer 2005 Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding Breast Cancer Res Treat 94 Suppl 1 S10 Abstract 16
25. NJ Robert PE Goss JN Ingle 2006 Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding J Clin Oncol 24 18s 10.1200/JCO.2005.04.1764 Abstract 550
26. J Ingle D Tu L Shepherd 2006 NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months J Clin Oncol 24 18s 10.1200/JCO.2005.04.1053 Abstract 549
27. KM Wasan PE Goss PH Pritchard 2005 The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 16 707 715 10.1093/annonc/mdi158
28. EA Perez RG Josse KI Pritchard 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a comparison study to NCIC CTG MA.17 J Clin Oncol 24 1 7 10.1200/JCO.2005.03.7234
29. A Brufsky 2006 Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update Semin Oncol 33 (2 Suppl 7) S13 S17 10.1053/j.seminoncol.2006.03.022
30. N Bundred I Campbell R Coleman 2006 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study) Eur J Cancer Suppl 4 48 Abstract 12
31. M Aapro PA Abrahamsson JJ Body 2008 Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 420 432 10.1093/annonc/mdm442
32. Hadji P, Body JJ, Aapro MS et al. (2008) Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. Epub ahead of print 29 April
33. TJ Whelan PE Goss JN Ingle 2005 Assessment of quality of life in MA.17: a randomized, placebo controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 6931 6940 10.1200/JCO.2005.11.181
34. Muss HB, Tu D, Ingle JN et al (2006) The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 100(Suppl 1). Abstract 102
35. PE Goss JN Ingle S Martino 2007 Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17 J Clin Oncol 25 1 6 10.1200/JCO.2006.07.7677
36. R Jakesz H Samonigg R Greil 2005 Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Study Group Trial 6a (ABSCG-6a) J Clin Oncol 23 10s Abstract 527
37. Mamounas E, Jeong J-H, Wickerham L et al (2006) Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100(Suppl 1). Abstract 49
38. A Goldhirsch JH Glick RD Gelber 2005 Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 Ann Oncol 16 1569 1583 10.1093/annonc/mdi326
39. AG Rieber RL Theriault 2005 Aromatase inhibitors in postmenopausal breast cancer patients J Natl Compr Canc Netw 3 309 314
40. EP Winer C Hudis HJ Burstein 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 619 629 10.1200/JCO.2005.09.121